The Technical Analyst
Tonix Pharmaceuticals [TNXP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Tonix Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.91% $0.160
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13.52 mill |
| EPS: | -6.85 |
| P/E: | -0.0200 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 84.49 mill |
| Avg Daily Volume: | 2.19 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0200 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.114 - 0.194 ( +/- 25.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
| 2024-02-27 | Lederman Seth | Buy | 1 903 680 | Stock Option |
| 2024-02-27 | Lederman Seth | Buy | 1 309 911 | Stock Option |
| 2024-02-27 | Lederman Seth | Buy | 235 320 | Stock Option |
| 2024-02-27 | Saenger Bradley | Buy | 282 000 | Stock Option |
| INSIDER POWER |
|---|
| 99.11 |
| Last 97 transactions |
| Buy: 77 144 979 | Sell: 389 187 |
Forecast:
16:00 - $0.154
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.154
Forecast 2: 16:00 - $0.154
Forecast 3: 16:00 - $0.154
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.160 (1.91% ) |
| Volume | 1.082 mill |
| Avg. Vol. | 2.19 mill |
| % of Avg. Vol | 49.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TNXP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TNXP
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Latest Press Releases
2024-04-01 16:15:00 - Press Release
Tonix Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Operational Highlights
Positive results from confirmatory phase 3 resilient study reported in december 2023 position tonmya™ for fibromyalgia for nda submission second half of 2024; pre-nda meeting with fda scheduled for second quarter 2024
2024-03-28 09:32:00 - Press Release
Tonix Pharmaceuticals Announces Pricing Of $4.4 Million Registered Direct Offering
Chatham, n.j., march 28, 2024 (globe newswire) -- tonix pharmaceuticals holding corp. (nasdaq: tnxp) (“tonix” or the “company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the company for the purchase and sale of 14,666,666 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered direct offering at a combined offering price of $0.30 per share and accompanying warrant. the warrants have an exercise price of $0.33 per share, will be exercisable commencing six months from the date of issuance and will expire five and one-half years following the date of issuance...
2024-03-25 08:00:00 - Press Release
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation From The Fda For Tnx-2900 For The Treatment Of Prader-willi Syndrome
Tnx-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating
2024-03-19 08:00:00 - Press Release
Tonix Pharmaceuticals Announces Transition To Fully Integrated Biopharmaceutical Company Expected On April 1, 2024
Zembrace® symtouch® and tosymra® will be marketed by tonix medicines, tonix's wholly-owned commercial subsidiary
2024-03-12 08:00:00 - Press Release
Tonix Pharmaceuticals Announces Presentation At Bio-europe Spring
Tonix recently reported results from second positive phase 3 trial of tonmya™ for the management of fibromyalgia in the u.s., new drug application (nda) submission to the fda planned for the second half of 2024 in japan, china and most countries in europe cyclobenzaprine is a new chemical entity chatham, n.j., march 12, 2024 (globe newswire) -- tonix pharmaceuticals holding corp. (nasdaq: tnxp) (tonix or the company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that seth lederman, m.d.
Latest News
2024-04-09 06:31:00 - InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.
2024-03-24 16:05:02 - InvestorPlace
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.
2024-02-25 14:12:12 - InvestorPlace
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.
2024-01-03 07:00:00 - GlobeNewsWire
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial
TNX-102 SL is a Non-Opioid Analgesic that Demonstrated Daily Pain Reduction Over Placebo (Primary Endpoint, p = 0.00005) and Showed Positive Effects Across All Six Key Secondary Endpoints in Recently Reported Phase 3 Trial
2023-12-11 07:00:00 - GlobeNewsWire
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
CHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday, December 14, 2023 via Zoom. Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m. ET.
2023-11-28 07:00:00 - GlobeNewsWire
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and host investor meetings at the following December investor conferences:
2023-10-31 20:16:00 - Market Watch
Tonix shares sink 29% on discontinued development on depression treatment
Shares of Tonix Pharmaceuticals TNXP fell Tuesday after the company said it would discontinue development of its treatment for major depressive disorder.
2023-10-12 07:00:00 - GlobeNewsWire
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.
2023-09-29 09:17:53 - InvestorPlace
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company priced a share offering. According to a press release from Tonix Pharmaceuticals, it has entered into a securities purchase agreement with certain healthcare institutional investors.
2023-08-17 07:00:00 - GlobeNewsWire
Tonix Pharmaceuticals to Present at the August Virtual Investor Summit
CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m. ET.